Home > Boards > US OTC > Biotechs > NorthWest Biotherapeutics Inc. (NWBO)

It’s my bet that when they unblind, they

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
meirluc Member Profile
 
Followed By 15
Posts 1,452
Boards Moderated 0
Alias Born 02/01/17
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/7/2020 5:27:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/26/2020 5:07:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 6/24/2020 6:02:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/8/2020 5:02:02 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2020 5:12:40 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 5/29/2020 5:28:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/27/2020 5:15:15 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/20/2020 5:06:06 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/12/2020 4:12:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:10:20 PM
Cannabis? CBD? That's Old News, A New Sector Bull Run Has Begun InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/9/2020 5:28:45 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2020 4:41:56 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 3/27/2020 2:47:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/16/2020 5:01:48 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/24/2020 5:07:15 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/15/2020 4:54:03 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/3/2020 5:04:36 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/13/2019 4:25:29 PM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 5:19:23 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 11/1/2019 6:00:56 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 10/28/2019 5:12:01 PM
On Watch this Week with Near-Term Potential Catalysts InvestorsHub NewsWire - 10/21/2019 8:00:00 AM
meirluc   Saturday, 06/27/20 01:37:56 PM
Re: sentiment_stocks post# 292119
Post # of 299081 
Quote:
It’s my bet that when they unblind, they find that all the unmethylated survivors at or over 3 years were treatment patients. Should this turn out to be the case, that would represent a tremendous step forward for unmethylated patients, for whom nothing seems to wo



I hope that you are right. Some time ago I estimated that of the approximately 23 unmethylated post 36(+) months survivors, 20 will be Treatment and 3 will be SOC.

However, for the reasons you stated above, I hope that I am wrong and that you are right although even with 20 long living Treatment vs. 3 long living SOC and given the 70% To 30% DCVax-L/SOC numerical patient ratio, DCVax-L would still have a clear edge.

With respect to methylated GBM, I hope that the IDH mutation work will shed some more light on the survival promoting ability of DCVax-L.

If long living (e.g. 3-5 year survivors) SOC patients, have a larger proportion of patients with the methylated GBM carrying the IDH1 mutation than the proportion of such patients found in the Treatment group, the importance of DCVax-L would be even more obvious.

For example if 4 of 7 Post 5 year SOC survivors have a GBM with the IDH1 mutation and 4 of 35 post 5 year Treatment survivors have a GBM carrying the mutation, the positive role of DCVax-L would become more apparent because the long survival of the SOC group seems to be more associated with the mutation's presence. DCVax-L may be important but so is the mutation.

In fact in this example, if we look at post 5 year survivors whose GBM did not carry the mutation, we would end up with 31 Treatment patients and only 3 SOC patients. This would be a ratio of more than 10 to 1 (31 vs. 3) in favor of the long living Treatment patients whereas before exclusion of long livers with the mutation, the ratio of long living Treatment to long living SOC patients was 5:1 (35 vs. 5). If this is correct, even in the absence of the mutation, early DCVax-L treatment would seem to be very efficacious whereas to achieve a prolonged survival of late treated patients, a co factor (IDH1 mutation) would often be required.

Time will tell whether the data concerning the mutation will be used to further highlight the importance of L.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist